Rating Change
HC Wainwright & Co. reiterated its Neutral rating on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) on October 20, 2026.
reiterateNASDAQ:EYPT
HC Wainwright & Co. Reiterates Neutral Rating on EyePoint Pharmaceuticals, Inc. (EYPT)
HC Wainwright & Co. reiterated its Neutral rating on EyePoint Pharmaceuticals, Inc.
At publication ·
What changed
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Neutral to Neutral
- Price at event
- $0.43
- Market capitalization
- $1.1B
At a glance
Key takeaways
- HC Wainwright & Co. maintained a Neutral rating on EyePoint Pharmaceuticals as of October 20, 2026.
Market Context
EyePoint Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $0.43 with a market capitalization of $1.1B. The stock has declined 74.5% over the past 52 weeks.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for EyePoint Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for EyePoint Pharmaceuticals, Inc.
Among the 10 most recent ratings: 2 Buy, 7 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 20, 2026 | JP Morgan | Underweight | N/A |
| Oct 20, 2026 | RBC Capital | Sector Perform | N/A |
| Oct 20, 2026 | Guggenheim | Neutral | N/A |
| Oct 20, 2026 | HC Wainwright & Co. | Neutral | N/A |
| Sep 02, 2026 | TD Cowen | Hold | N/A |
Related Tools: Analyst Ratings Dashboard | View EYPT Stock Page
Frequently Asked Questions
What does the Neutral rating mean for EYPT?
A rating of Neutral from HC Wainwright & Co. reflects the analyst's outlook on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the EYPT forecast page.